Stockreport

ARS Pharmaceuticals GAAP EPS of -$0.52 misses by $0.05, revenue of $32.5M beats by $3.82M [Seeking Alpha]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF As of September 30, 2025, ARS Pharma had cash, cash equivalents, and short-term investments of $288.2 million, with 98,844,178 shares of common stock outstanding. Mor [Read more]